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INTRODUCTION
The global HIV epidemic continues to expand with
an estimated three million people newly infected in
2007.1 Over the decades, the epidemic, once dominated
by infected males, has become increasingly feminized.
In sub-Saharan Africa, where about two-thirds of the
global disease burden resides, 57% of adults living
with HIV are women.2 As more women contract the
virus, the number of children infected from their
mothers has been growing worldwide. The epidemic
in children parallels that among women on account
of perinatal transmission. Indeed, an estimated
370,000 children acquired HIV in 2007 alone, with
more than 90% of the infections occurring through
mother-to-child transmission.1
A combination of antiretroviral therapy and elective
caesarean sections reduces the rate of vertical
transmission to <2%.3, 4  Elective cesarean section
independent of antiretroviral therapy decreases the risk
of  HIV vertical transmission from mother to baby.5, 6
Indeed when viral loads are more than 1000 copies
per milliliter, the benefit from elective caesarean
delivery is beyond that achieved by antiretroviral therapy
alone.6 However, a caesarean section is a major surgical
intervention that has well-reported complications.
There is a higher incidence of morbidity after caesarean
section compared with vaginal childbirth in healthy
women and routine delivery by caesarean section
maybe potentially dangerous in low resource settings.6
Women infected with HIV have been reported to be
more susceptible to such complications which include
prolonged hospital stays and increased infective
complications compared with HIV- negative women.7
It has been suggested that the higher complication rate
may be related to an impaired immune response. The
incidence of complications is significantly increased
when the CD4+ count is <200/ml. 8
Anesthetic considerations
HIV is a multi-organ disease which may be complicated
either by opportunistic infections, tumors, substance
abuse, or antiretroviral therapeutic drugs, which all can
have an impact on anesthesia. It poses challenges at
the time of  surgery, anesthesia and for those involved
in obstetric management. During preoperative
evaluation, assessment of risk should focus on the
patient’s immunological and clinical status, type of
surgery and anesthesia. and the coexistence of
opportunistic infections and malignancies. This will
allow a good prediction for the perioperative risk of
the HIV-patient to be constructed.9 The history should
include evaluation of concurrent treatments with
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antiretroviral or anti-opportunistic drugs. The
laboratory work up should include complete blood
count, clotting functions, glucose, liver and renal
functions test. Verification of  the immunological status
i.e. the CD4+ lymphocyte cell count and viral load
during the previous 3 months is important.9 Chest
radiograph and electrocardiogram should be
performed in all patients. Patients with a history or
signs of cardiac or pulmonary dysfunction should
undergo a more thorough evaluation (blood gases,
echocardiography etc). One must remember that these
patients have often been subjected to cardiotoxic
antiretroviral drugs, may be in a hypercoagulable state,
may have accelerated coronary arteriosclerosis, and
often have decreased left ventricular contractility.10,11,12
Factors that need to be considered when administering
general anesthesia include the possible effects of
anesthesia and opioids on the immune system, the
pulmonary and neurologic status of the HIV patient,
and possible interactions with anti-HIV medications.
Laboratory data suggest a detrimental effect of
opioids on immune function.9, 13 However, the clinical
significance of  short term opioid administration during
general anesthesia is unclear and there are not enough
clinical data available to justify its avoidance.9 Several
studies indicate that general anesthesia and oxidants
may have a negative effect on immune function.
Although this immune-suppressive effect is probably
of little clinical importance in healthy individuals, the
implications for the HIV- infected patient are
unknown.14, 15 Immune suppression resulting from
general anaesthetics occurs within fifteen minutes of
induction and may persist for as long  as three to eleven
days. 15, 16 Postoperative immunosuppression may last
longer in inherently immunosuppressed patients and
may predispose to the development of postoperative
infections or facilitate tumour growth of  metastasis.16
Before administration of any anesthetics, the
anesthesiologist should be aware of the possible toxic
side effects or to the possible interaction of
antiretroviral drugs with the anesthetics. Some of  these
adverse effects may mimic signs and symptoms of
the HIV disease itself.9 During pregnancy, dosing must
be taken into consideration as blood volume and
volume of  distribution changes during pregnancy. In
addition, there are potential toxic drug effects on the
fetus and the newborn.17, 18 Side effects may also result
from drugs used for prevention or treatment of
opportunistic infections. For example, neuropathy or
myopathy may dictate change of  anesthetic techniques.
Anemia and thrombocytopenia are major toxic side
effects of zidovudine (a nucleoside reverse
transcriptase inhibitor). Protease inhibitors can affect
glucose metabolism. Foscarnet (an antiviral phosphonic
acid derivative) and protease inhibitors can cause renal
toxicity. Foscarnet can also alter calcium and magnesium
balance.9 Other side effects include increased liver
enzymes (trimethoprim-sulfamethoxazole), broncho-
spasm (aerosolized pentamidine), and ventricular
arrhythmias (intravenous pentamidine).9
Protease inhibitors such as ritonavir, are inhibitors of
CYP450, which impair the metabolism of multiple
anesthetics and analgesics, such as midazolam and
fentanyl, and cardiac drugs, such as amiodarone and
quinidine.9, 19. Nevirapine is an inducer of CYP450,
and therefore increasing doses of anesthetic drugs may
be required in patients receiving the drugs. 9, 20
Etomidate, atracurium, remifentanil and desflurane are
not dependent on CYP450 hepatic metabolism, and
therefore, are preferable drugs.9 The complications
associated with the use of sucinylcholine, such as
hyperkalemia or hyperpyrexia, are only a potential risk
to be considered in the HIV patient with progressive
neuropathy, myopathy, and muscle wasting. No such
complication in HIV patient has been reported in the
literature; hence the use of succinylcholine is not
absolutely contraindicated.9,21.
The presence of neurologic manifestations, such as
overt dementia, may increase brain sensitivity to sedative
or psychoactive drugs (opioids, benzodiazepines, and
neuroleptics).9 Opportunistic infections e.g.
toxoplasmosis may be associated with increased
intracranial pressure. Because these infections respond
rapidly to medical therapy, surgery should be
postponed whenever possible when they are present.
Increased ICP and CNS infections (meningitis,
encephalopathy, or myelopathy) are contraindications
to neuraxial anesthesia.22 Pulmonary complications can
occur as a consequence of  opportunistic infections.
This may lead to respiratory distress and hypoxemia,
aggravated by a decrease in functional residual capacity
seen during pregnancy. Regional anesthesia may be a
preferable technique in these patients.9 Indeed, an
increase in postoperative morbidity and mortality after
general anesthesia compared with regional anesthesia
has been reported. The stress response to surgery may
be more profound after general anesthesia, which in
turn may lead to impaired immune function.23
Regional anesthesia has been shown to be associated
with reduced morbidity and mortality in a wide range
of patients, including HIV positive parturients having
cesarean delivery under spinal anesthesia.23 Regional
anesthesia has the advantage of not interfering with
the immune system or with antiretroviral drugs.
Contraindications to regional anesthesia in these patients
are sepsis and platelet abnormalities. The presence of
neuropathy may reduce the appeal of regional
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anesthesia but there are no data to contradict its use.9
It’s use in HIV treated parturients who underwent CS
has not been associated with increased peri-operative
complications or changes in immune function or viral
load.23, 24
Postdural puncture headache may occur after regional
anesthesia and may necessitate epidural blood patch.
There is no evidence to contraindicate the use of the
patch in HIV-positive patients. Its use in HIV treated
parturients who underwent CS had not been associated
with peri-operative complications or changes in
immune function or viral load.25 In addition, central
nervous system involvement occurs early during the
course of HIV infection and introduction of HIV virus
into a previously virus-free CNS after penetration of
a subarachnoid space during spinal anesthesia is not
really a concern.26 However, the small numbers
reported in studies may justify a conservative
management as a first choice. 27 Overall, the risk with
regional anesthesia is lower than if general anesthesia
with prolonged artificial ventilation were
administered.23, 28
HIV Transmission in the Health Care Setting.
Contamination of anesthetic equipment is a potential
route of HIV transmission. Although, airway devices
are not reused between patients, other anesthetic
equipment can potentially become contaminated by
patients’ secretions. Contamination of  laryngoscope
blades and handles with visible and occult blood occurs
frequently. In one study, 65 laryngoscope blades and
handles identified as ready for patient use were
examined, and 26 (40%) were contaminated with
occult blood. 29 Heat and moisture exchange filters
effectively filter bacteria and viruses thereby minimizing
the risk of contamination of respiratory equipment.30
If a hydrophobic filter is used with each patient, the
use of a disposable respiratory circuit is not required.31
Techniques such as the use of  a common syringe with
anesthetic drugs for several patients are a potential
hazard and are not acceptable practice.32
HIV can be transmitted from the infected patient to
the care provider as a result of exposure to infected
body fluids. Deep subcutaneous or intramuscular
exposure to a blood-contaminated needle from a
patient with high HIV viraemia appears to be the worst
type of contact.33, 34 Most contaminated percutaneous
injuries occur during multistep procedures, during
recapping of needles or when contaminated sharps
are not discarded safely.35 Double gloving during
surgery prevents perforations of the inner glove, but
its effect on infections is unknown. 36, 37 It is
recommended that double gloves are used routinely
in all surgical procedures in view of the significantly
higher protection it provides. Preventive efforts can
reduce the risk of exposure, but not eliminate them,
and comprehensive guidelines to this end have been
published.38 Following an accident with high – risk body
fluid postexposure prophylaxis (PEP) is recommended
to commence as soon as possible after the injury,
ideally within 1-2 h.34
The risk of transmission from anesthetist to patient
appears to be low.38 Using the risks of  transmission
and the rates of percutaneous injuries, estimates have
been made regarding the risk of an infected health
care worker transmitting blood borne pathogens to
patients. The estimated probability of  transmission
from an infected surgeon to a patient during a single
procedure is 0.00024-0.0024% for HIV and 0.024-
0.24% for HBV if the surgeon is positive for Hepatitis
B e antigen (HBeAg). The estimated probability of
transmission to at least one patient during 3,500
procedures (estimated to be performed during an
HIV-infected surgeon’s remaining working life) is 0.81-
8.1% for HIV; 57-100% for HBV if  the surgeon is an
HBeAg carrier. These estimates represent population
averages and may not necessarily apply to a particular
procedure performed by a particular surgeon, for
which the risk may be considerably lower or higher
than the estimated average.
CONCLUSION
Anesthetists should be familiar with the overall risk of
anesthesia and surgery in the HIV positive parturient.
In addition, an understanding of the impact of HIV
on anesthesia and the possible drug-drug interactions
may help to guide the choice of  anesthetic techniques.
Finally, the possibility of  transmission in the health care
setting highlights the need for anesthetists to enforce
rigorous infection control policies to protect themselves,
other health workers and their patients.
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